P
9.39
-0.48 (-4.86%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Precision BioSciences, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 4.0 |
| 相对估值 | NA |
| 财务健康 | 1.4 |
| 宏观环境 | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.29 |
|
Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 10.94% |
| 机构持股比例 | 42.73% |
该时间范围内无数据。
该时间范围内无数据。
投资组合